EU states warn of risks to vaccination credibility as Pfizer slows supplies

The European Union governments said the credibility of their vaccination programmes was at risk on Friday after US pharmaceutical firm Pfizer announced a temporary slowdown of deliveries of its COVID-19 vaccines.

Shots developed by Pfizer with its German partner BioNTech began being delivered in the EU at the end of December, but around nine of the 27 EU governments complained of "insufficient" doses at a meeting this week, a participant said.

Pfizer initially said deliveries were proceeding on schedule, but then on Friday announced there would be a temporary impact on shipments in late January to early February caused by changes to manufacturing processes to boost output.

"This situation is unacceptable," the health and social affairs ministers of six EU states said in a letter to the EU commission about the Pfizer delays. "Not only does it impact the planned vaccination schedules, it also decreases the credibility of the vaccination process," the ministers, from Sweden, Denmark, Finland, Lithuania, Latvia and Estonia said.

Germany, Europe's largest purchaser of the Pfizer vaccine, called the decision surprising and regrettable, while Canada said it was also affected, because its supplies come from a Pfizer factory in Belgium.

Norway and Lithuania had earlier said the company was reducing supplies across Europe. "What we want is for Pfizer-BioNTech to restore their deliveries to the agreed schedule," Lithuanian health minister Arunas Dulkys told Reuters.

The President of the European Commission Ursula von der Leyen said Pfizer had reassured her that deliveries planned to the EU in the first quarter would not be delayed.

PROMISED INCREASE

Pfizer, which is trying to deliver millions of doses at a breakneck pace to curb a pandemic that has already killed nearly 2 million people, said its changes would "provide a significant increase in doses in late February and March."

Neither the company nor the EU have indicated how many doses are expected in the first quarter. A second EU source told Reuters that in another EU internal meeting with diplomats on Wednesday, an EU Commission official said deliveries would be limited at least until March, with production set to be ramped up in earnest only by September.

Pfizer and BioNTech have contracts with the EU to supply up to 600 million doses this year. They have agreed to deliver 75 million shots in the second quarter and more later in the year.

The EU has also approved the vaccine developed by US biotech firm Moderna, which began deliveries this week. Moderna has committed to delivering 10 million doses by the end of March and 35 million each in the second and third quarter. Another 80 million doses are also to be delivered this year but without a clear timetable yet.

PRO RATA?

Pfizer and Moderna have not published detailed calendars of deliveries for each of the 27 EU countries, which are expected to receive a portion of vaccines in proportion to their share of the EU's 450 million population.

Pfizer said the information was confidential, while Moderna said: "At this stage we can only confirm that the doses will be distributed on a pro-rata basis between EU countries." But deliveries do not seem to be proceeding evenly.

The German Health Ministry website says the country, with a population of 83 million, will receive nearly 4 million Pfizer doses by the end of January.
Romania, with a population four times smaller, says it expects to receive only 600,000 doses in the same period. Bulgaria, with less than one-tenth of Germany's population, expects to receive only about 60,000 Pfizer shots in January.

A spokesman for the EU Commission said national timetables partly depended on contracts signed by each state. It is not clear whether all EU governments ordered their full allocation of vaccines, as this information is confidential.

The EU has secured nearly 2.3 billion doses of COVID-19 vaccines and candidates from six firms, but most are yet to be approved. Decisions on AstraZeneca and Johnson & Johnson vaccines are expected in late January and in February respectively.

Reuters